STLN · Starling Oncology, Inc.

$6.54 +0.14 (+2.19%)

Market Cap

$652.26M

101.92M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Program Authorized

2,000,000 shares

as of 2023-08-28 · not restated in filings since 2025-03-26

Cash spent on buybacks by quarter

Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.

Repurchase History

Fiscal Year Ended	Cash Spent	Shares	Avg Price	Source
2024-12-31	$0	—	—	10-K, filed 2025-03-26
2023-12-31	$1,019,000	1,500,000	—	10-K, filed 2025-03-26
2022-12-31	$9,000,000	1,500,000	—	10-K, filed 2024-03-28
2021-12-31	$0	—	—	10-K, filed 2023-03-16

Quarter Ended	Cash Spent	Shares	Avg Price	Source
2024-12-31	$0 Δ	—	—	10-K, filed 2025-03-26
2024-09-30	$0 Δ	—	—	10-Q, filed 2024-11-13
2023-12-31	$0 Δ	—	—	10-K, filed 2025-03-26
2023-09-30	$125,000 Δ	—	—	10-Q, filed 2024-11-13
2022-12-31	$0 Δ	—	—	10-K, filed 2024-03-28
2022-09-30	$0 Δ	—	—	10-Q, filed 2023-11-08
2022-06-30	$9,000,000	1,500,000	—	10-Q, filed 2022-08-09
2021-12-31	$0 Δ	—	—	10-K, filed 2023-03-16
2021-09-30	$0 Δ	—	—	10-Q, filed 2022-11-09

Key facts CIK 1799191 CUSIP 68236X100 13F (30d) 128 filings 128 filers Visit website Investor relations